Type 2 diabetes (T2D) patients with low-density lipoprotein cholesterol (LDL-C) less than 2.0 mmol/L are at increased risk for cardiovascular (CV) events. The study was conducted by Shahnam Sharif MD and published online in Diabetes Care.
A study was conducted by Mohammad Movahedi, M.D., Ph.D., for the link between glucocorticoid treatment and risk for diabetes mellitus in rheumatoid arthritis patients. Researchers found that there is an increased risk for diabetes mellitus (DM) with the treatment. The study was done on the basis of the dosage and timing of glucocorticoid use. The study findings were published in the Arthritis & Rheumatology.
In order to develop disposable continuous glucose monitor (CGM), Medtronic (MDT) has partnered with Qualcomm. The product will give better care and treatment to type 2 diabetes (T2D) patients when needed with the intelligent care with the device. Medtronic signed a number of partnerships with different companies during last 1 year in the field of diabetes. Some of the companies are
They acquired Smith & Nephews gynecology business recently.
The research shows that chances of major CVD in type 2 diabetes (T2D) patients increase with respect to the number of microvascular disease manifestations. Microvascular diseases are
The research findings were published in the Lancet Diabetes & Endocrinology.
UK health experts called for 100,000 weight loss surgeries to reduce BMI of the type 2 diabetes (T2D) patients. Studies indicate that weight loss surgery will reverse type 2 diabetes (T2D) as BMI reduces. Major health risks with type 2 diabetes (T2D) include
Even though high risk associated with diabetes, it was reported that less than 50% of patients change their lifestyle or drugs to control high blood sugar levels.
Proteins are normally soluble in water. If proteins could not fold properly, they become insoluble and deposited in organs and tissues. The deposited proteins disrupt the function of body organs. Amyloids are proteins that fold incorrectly. Accumulation of them in our organs is called amyloidosis. Researchers from Uppsala University, Sweden found that brain amyloids will influence the growth of fine fiber in the pancreas. Islet amyloid polypeptide (IAPP) is normally associated with type 2 diabetes (T2D) patients and brain function loss and brain cell death happen with the accumulation of IAPP.
The study conducted by Korea Basic Science Institute concluded that a TSPAN2, a protein found in the pancreas, can play important role in preventing the death of beta cells induced by high blood glucose levels. Researchers say newer medicines have to be developed targeting TSPAN2 protein to stop loss or death of beta cells. Study author of the research was Ik-Soon Jang and the research findings were published in the FASEB Journal.
Medicinal Products Committee of European regulator supported approval of AstraZeneca's diabetes combination. FDA denied approval for the same drug 7 months back, asking for more information. The manufacturer says US regulator may not approve diabetes combination drug as it contains high levels of potassium. AstraZeneca's diabetes drug is the combination of saxagliptin and dapagliflozin.
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.